Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nebraska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nebraska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nebraska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Madhu Midathada (NPI 1265511034)

Field	Value
Entity Type	Individual
Organization	Madhu Midathada
Address	4004 Pioneer Woods Dr
City	Lincoln
State	NE
ZIP	68506
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	November 3, 2006

Payer Source	Total Paid
Medicare	$2.3M
Medicaid	$0

Key Findings

This provider reports Total Medicare revenue of $2.3M and Total Medicaid revenue of none (no Medicaid billing on file), so the observable billing footprint is effectively single-payer Medicare for analysis purposes. The provider’s NPI was enumerated on 2006-11-03 (~20 years ago), indicating an established billing history to Medicare over roughly two decades.

Revenue is highly concentrated in a small number of high-cost oncology drugs: the precomputed top 3 Medicare codes by revenue account for 62.9% of this provider's total Medicare revenue. Those top three are J9271 ($662.2K, 29.8% of Medicare revenue), J9144 ($485.6K, 21.9%), and J9299 ($250.6K, 11.3%), which together drive the majority of reported Medicare dollars.

The code mix and descriptors identify a medical oncology practice centered on in-office infusions and biologic/immune therapies: high-revenue J-codes include J9271 (pembrolizumab), J9144 (daratumumab), and J9299 (nivolumab), and the provider also bills supportive and adjunctive therapy codes such as J0897 (denosumab), J2506/Q5108 (pegfilgrastim), J1439 (ferric carboxymaltose), and J1569 (immune globulin). Administration and chemotherapy infusion procedure codes (for example 96413, 96365, 96417) appear in the top-25, reinforcing an infusion-centered operations model rather than a primarily diagnostic or surgical practice.

Competitive standing across specific drug lines is mixed: J9144 ranks #133 of 615 providers nationally (78th percentile; typical, unremarkable volume) indicating stronger-than-average participation in daratumumab relative to peers, while J9271 ranks #652 of 1841 (64th percentile; typical, unremarkable volume) showing a modest national position for pembrolizumab and J9299 ranks #342 of 505 (32th percentile; typical, unremarkable volume) indicating comparatively lower nivolumab volume. Overall this reads as a modest-to-moderate national presence with pockets of relatively higher activity for certain agents rather than dominant market share.

Evaluation-and-management and ancillary services show above-typical activity on some metrics: 99214 ranks #20405 of 479517 providers nationally (96th percentile; notably above typical national volume for this code), while 99215 and 99213 appear at the 92th percentile (typical, unremarkable volume) for their respective national rank statements. Several common lab and phlebotomy codes (80053, 85025, 36415) also appear in high national percentiles but are labeled in the dataset as typical, unremarkable volume, which together suggests steady outpatient follow-up and monitoring workloads in addition to infusion services.

The revenue profile shows material exposure to high-cost biologics and to biosimilar substitution dynamics: the top-25 includes biosimilar entries such as Q5118 (bevacizumab-bvzr) that rank #36 of 161 (78th percentile; typical, unremarkable volume) and biosimilar pegfilgrastim Q5108 at more mid-range national standing. Given that the largest Medicare dollars come from a few branded biologics, changes in formulary placement, biosimilar uptake, or payer reimbursement could meaningfully affect this provider’s Medicare revenue concentration.

Absence of Medicaid billing (noted as "none below") means there is no in-state Medicaid footprint to evaluate and the provider should be considered effectively single-payer in the Medicare dataset; this limits any conclusions about state-level Medicaid competitiveness or participation and suggests payer mix and contracting analyses should focus on Medicare and likely commercial channels outside the dataset.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

81 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	15,400	$40	$662.2K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	12,780	$40	$485.6K
J9299	Injection, nivolumab, 1 mg	10,440	$20	$250.6K
J0897	Injection, denosumab, 1 mg	8,640	$20	$155.5K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	4,220	$40	$151.9K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	3,900	$20	$85.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	790	$90	$72.3K
J1439	Injection, ferric carboxymaltose, 1 mg	60,000	$1	$60K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	530	$90	$48K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	420	$100	$40.3K

Showing 1–10 of 81

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 81 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nebraska Distribution

Madhu Midathada — 7 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nebraska

Full comparison — all codes billed, vs. state median

81 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	13	30	14,400	$40	$671.6K
J9299	12	10	19,300	$20	$444.5K
J9144	3	10	10,440	$40	$434.6K
J1569	6	10	5,980	$40	$224.3K
Q5118	1	10	2,540	$20	$66.9K
J0897	20	200	2,040	$20	$62.7K
J2506	4	20	460	$90	$40.5K
Q5108	5	10	410	$90	$35.7K
J1439	2	30	25,880	$1	$26.4K
J9217	52	50	110	$130	$20.6K

Showing 1–10 of 81

Related Providers

Other providers that share a Tax Identification Number (TIN) with Madhu Midathada, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Alegent Creighton Clinic	NE	Family Medicine Physician	$0	$43.2M
The Physician Network	NE	Family Medicine Physician	$0	$3.1M
Eric Avery	NE	Hematology & Oncology Physician	$3.1M	$0
Kailash Mosalpuria	NE	Hematology & Oncology Physician	$2.9M	$0
Chi Health Clinic Specialty, LLC	NE	Hospitalist Physician	$0	$2.6M
Sakeer Hussain	IA	Hematology & Oncology Physician	$1.9M	$0
Steven Dunder	NE	Hematology & Oncology Physician	$1.7M	$0
Haris Zahoor	TX	Medical Oncology Physician	$1.6M	$0
Wallace Peterson	NE	Hematology & Oncology Physician	$1.5M	$0
Irfan Vaziri	NE	Medical Oncology Physician	$1.4M	$0

Nearby Providers

Other providers in the same ZIP code as Madhu Midathada, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Bryan Medical Center	NE	General Acute Care Hospital	$0	$56.9M
Integrated Behavioral Health Services	NE	Community/Behavioral Health Agency	$0	$16.3M
Nebraska Emergency Medicine PC	NE	Emergency Medicine Physician	$0	$14.9M
Firstcare Home Health Of Eastern Nebraska, Inc	NE	Home Health Agency	$0	$6.6M
Matthew Wood	NE	Ophthalmology Physician	$3.9M	$0
Daniel Chruscicki	NE	Ophthalmology Physician	$3M	$0
Integrated Cardiology Group LLC	NE	Cardiovascular Disease Physician	$0	$2.7M
Pathology Medical Services PC	NE	Anatomic Pathology & Clinical Pathology Physician	$0	$2.1M
Rockledge Smiles LLC	NE	General Practice Dentistry	$0	$2.1M
Eye Surgical Associates, LLC	NE	Ophthalmology Physician	$0	$1.7M

Madhu Midathada — Billing Profile & Reimbursement Data

Sign up for Madhu Midathada — Billing Profile & Reimbursement Data policy alerts

Madhu Midathada — Billing Profile & Reimbursement Data

Sign up for Madhu Midathada — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References